Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Logicbio Therapeutics Inc (LOGC)

Logicbio Therapeutics Inc (LOGC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 296,246
  • Shares Outstanding, K 22,494
  • Annual Sales, $ 0 K
  • Annual Income, $ -17,620 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.41
  • Number of Estimates 3
  • High Estimate -0.37
  • Low Estimate -0.43
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.00 +15.45%
on 07/09/19
15.29 -16.94%
on 06/21/19
-2.20 (-14.77%)
since 06/19/19
3-Month
11.00 +15.45%
on 07/09/19
20.07 -36.72%
on 05/28/19
+0.55 (+4.53%)
since 04/18/19

Most Recent Stories

More News
LogicBio Therapeutics Receives Rare Pediatric Disease Designation for LB-001 for the Treatment of Methylmalonic Acidemia

LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced the U.S. Food and Drug Administration...

LOGC : 12.70 (-3.57%)
LogicBio Secures Up To $20 Million Debt Facility with Oxford Finance LLC and Horizon Technology Finance

LogicBio Therapeutics, Inc. (Nasdaq: LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases, today announced the closing of a $20 million...

LOGC : 12.70 (-3.57%)
HRZN : 11.83 (-1.33%)
Global $6.19Bn Programmable Logic Devices (PLDs) Market to 2024 with Xilinx, Intel, and Microchip Technology Dominating - ResearchAndMarkets.com

The "Global Programmable Logic Devices (PLDs) Market - Forecasts from 2019 to 2024" report has been added to ResearchAndMarkets.com's offering.

MCHP : 92.31 (-0.64%)
LOGC : 12.70 (-3.57%)
LogicBio Therapeutics: 1Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ LogicBio Therapeutics Inc. (LOGC) on Tuesday reported a loss of $7.7 million in its first quarter.

LOGC : 12.70 (-3.57%)
LogicBio Reports First Quarter 2019 Financial Results and Provides Business Updates

LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases, today reported financial results and provided...

LOGC : 12.70 (-3.57%)
Kamada (KMDA) to Report Q1 Earnings: What's in the Cards?

Kamada (KMDA) is expected to provide updates on pipeline candidates during the first-quarter earnings call.

KMDA : 5.94 (-0.50%)
LOGC : 12.70 (-3.57%)
CTST : 2.77 (-5.46%)
TAK : 17.38 (-0.11%)
Dr. Reddy's (RDY) to Report Q4 Earnings: What's in Store?

Dr. Reddy's (RDY) will provide updates on new generic filings and new drug applications, when it reports fourth-quarter fiscal 2019 results.

RDY : 37.72 (-1.57%)
LOGC : 12.70 (-3.57%)
CTST : 2.77 (-5.46%)
BIIB : 231.27 (-0.41%)
LogicBio Therapeutics Receives FDA Orphan Drug Designation for LB-001 for the Treatment of Methylmalonic Acidemia

LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced that the U.S. Food and Drug Administration...

LOGC : 12.70 (-3.57%)
LogicBio Therapeutics Expands Leadership Team and Bolsters Capabilities to Support GeneRide(TM) Platform Development and Advancement of Lead Program into Clinic

LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today announced a significant expansion of its leadership team to continue...

LOGC : 12.70 (-3.57%)
LogicBio Therapeutics: 4Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ LogicBio Therapeutics Inc. (LOGC) on Monday reported a loss of $7.1 million in its fourth quarter.

LOGC : 12.70 (-3.57%)
Trade LOGC with:

Business Summary

LogicBio Therapeutics Inc. is a genome editing company. It focuses on developing medicines to treat rare diseases in patients with significant unmet medical needs. The company's technology platform consists of GeneRide(TM). LogicBio Therapeutics Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 13.10
1st Resistance Point 12.90
Last Price 12.70
1st Support Level 12.60
2nd Support Level 12.50

See More

52-Week High 20.07
Fibonacci 61.8% 14.96
Fibonacci 50% 13.39
Last Price 12.70
Fibonacci 38.2% 11.81
52-Week Low 6.70

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar